Beta-2 microglobulin is a protein of major histocompatibility complex class I molecules, which is used as tumor marker for certain blood cancers. It is present on all nucleated cells. The beta-2 microglobulin is tested in plasma, serum, or urine samples. The beta-2 microglobulin level in the sample helps detect disease activity; for example, low level of beta-2 microglobulin in serum indicates less disease activity, while high levels indicate higher disease activity. In many hematological disorders, beta-2 microglobulin level works as a highly sensitive marker. Beta-2 microglobulin is used as a prognostic marker to test disease activity such as lymphoma, leukemia, and multiple myeloma. High levels of beta-2 microglobulin in urine samples can help detect tubular disorders of the kidney. However, this testing cannot be used to diagnose a specific disease. It only provides additional information regarding a patient’s prognosis.
Driving factors of the global Beta-2 Microglobulin Testing Market include rising geriatric population and increasing prevalence of blood cancer. However, high cost, patent protection, regulatory constraints, technological edge, and limitations are anticipated to restrain the market. The global beta-2 microglobulin testing market can be segmented based on application, end-users, sample type, and region. In terms of application, the market can be divided into kidney diseases, tumor markers, urinalysis, ELISA, blotting, life science, testing or assay validation, antibody production, immunoassays, controls, and calibrators & standards. The tumor markers segment held a large market share in 2016 owing to the high prevalence of cancer. The kidney diseases and urinalysis segments are anticipated to witness strong growth in the next few years. Growth of these segments can be attributed to rise in the geriatric population.
Based on end-user, the global beta-2 microglobulin testing market can be segmented into hospitals, academic, and research institutes, and diagnostic centers. The hospitals segment held the major market share in 2016 due to government initiatives for spreading awareness about the benefits of pre-determination of cancer. The academic and research institutes segment is expected to gain market share in the next few years owing to high demand for advancements in research & development.
Request to View Brochure of Report -
In terms of sample type, the global beta-2 microglobulin testing market can be classified into urine, blood, and cerebrospinal fluid. The blood sample segment accounted for high market share in 2016, attributed to rising prevalence of lymphoma, multiple myeloma, infections such as HIV, cytomegalovirus, and inflammatory disorders. The urine sample segment is anticipated to grow during the forecast period owing to rising population of people above 50 years and increasing prevalence of kidney disorders.
Geographically, the global beta-2 microglobulin testing market can be divided into Asia Pacific, Europe, North America, Latin America, and Middle East & Africa. North America held the largest share of the beta-2 microglobulin test market in 2016, owing to the technological advancements, which have created numerous opportunities for determining specific tumors, monitoring biological response to cancer therapy, and genetic predisposition. Increasing geriatric population further fueled the market in the region. Europe held the second largest market share in 2016 owing to the high prevalence of cancer. The market in Asia Pacific is expected to witness strong growth during the forecast period due to increasing awareness and government initiatives in India and China.
Key players in the global beta-2 microglobulin testing market are Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Sequenom, QIAGEN, Cepheid, Biomedical diagnostics, bioMérieux, Inc., and other prominent players.
Comments
Post a Comment